Research programme: peptide-based radiopharmaceuticals - 48Hour Discovery/RayzeBio
Alternative Names: Research programme: peptide-based radiotherpeutics - 48Hour Discovery/RayzeBioLatest Information Update: 28 Feb 2024
At a glance
- Originator 48Hour Discovery; RayzeBio
- Class Antineoplastics; Peptide drug conjugates; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer